97 related articles for article (PubMed ID: 28487238)
1. The recipient CCR5 variation predicts survival outcomes after bone marrow transplantation.
Horio T; Mizuno S; Uchino K; Mizutani M; Hanamura I; Espinoza JL; Onizuka M; Kashiwase K; Morishima Y; Fukuda T; Kodera Y; Doki N; Miyamura K; Mori T; Takami A
Transpl Immunol; 2017 Jun; 42():34-39. PubMed ID: 28487238
[TBL] [Abstract][Full Text] [Related]
2. Recipient PTPN22 -1123 C/C genotype predicts acute graft-versus-host disease after HLA fully matched unrelated bone marrow transplantation for hematologic malignancies.
Espinoza JL; Takami A; Onizuka M; Morishima Y; Fukuda T; Kodera Y; Akiyama H; Miyamura K; Mori T; Nakao S;
Biol Blood Marrow Transplant; 2013 Feb; 19(2):240-6. PubMed ID: 23025987
[TBL] [Abstract][Full Text] [Related]
3. A donor thrombomodulin gene variation predicts graft-versus-host disease development and mortality after bone marrow transplantation.
Nomoto H; Takami A; Espinoza JL; Matsuo K; Mizuno S; Onizuka M; Kashiwase K; Morishima Y; Fukuda T; Kodera Y; Doki N; Miyamura K; Mori T; Nakao S; Ohtake S; Morishita E
Int J Hematol; 2015 Oct; 102(4):460-70. PubMed ID: 26246110
[TBL] [Abstract][Full Text] [Related]
4. Toll-like receptor genetic variations in bone marrow transplantation.
Uchino K; Mizuno S; Sato-Otsubo A; Nannya Y; Mizutani M; Horio T; Hanamura I; Espinoza JL; Onizuka M; Kashiwase K; Morishima Y; Fukuda T; Kodera Y; Doki N; Miyamura K; Mori T; Ogawa S; Takami A
Oncotarget; 2017 Jul; 8(28):45670-45686. PubMed ID: 28484092
[TBL] [Abstract][Full Text] [Related]
5. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry.
Farag SS; Bacigalupo A; Eapen M; Hurley C; Dupont B; Caligiuri MA; Boudreau C; Nelson G; Oudshoorn M; van Rood J; Velardi A; Maiers M; Setterholm M; Confer D; Posch PE; Anasetti C; Kamani N; Miller JS; Weisdorf D; Davies SM;
Biol Blood Marrow Transplant; 2006 Aug; 12(8):876-84. PubMed ID: 16864058
[TBL] [Abstract][Full Text] [Related]
6. Survival and graft-versus-host disease in patients receiving peripheral stem cell compared to bone marrow transplantation from HLA-matched related donor: retrospective analysis of 334 consecutive patients.
Campregher PV; Hamerschlak N; Colturato VA; Mauad MA; de Souza MP; Bouzas LF; Tavares Rde C; Barros JC; Chiattone R; Paz A; Silla L; Vigorito AC; Miranda E; Funke VA; Flowers ME
Eur J Haematol; 2015 Nov; 95(5):421-5. PubMed ID: 25645430
[TBL] [Abstract][Full Text] [Related]
7. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
8. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program.
Ozawa S; Nakaseko C; Nishimura M; Maruta A; Cho R; Ohwada C; Sakamaki H; Sao H; Mori S; Okamoto S; Miyamura K; Kato S; Kawase T; Morishima Y; Kodera Y;
Br J Haematol; 2007 Apr; 137(2):142-51. PubMed ID: 17391494
[TBL] [Abstract][Full Text] [Related]
9. PD-1 genotype of the donor is associated with acute graft-versus-host disease after HLA-identical sibling donor stem cell transplantation.
Santos N; Rodríguez-Romanos R; de la Cámara R; Brunet S; Nieto JB; Buño I; Martínez C; Jiménez-Velasco A; Vallejo C; González M; Solano C; Ferrá C; Sampol A; Pérez-Simón JA; López-Jiménez J; Díez JL; Gallardo D;
Ann Hematol; 2018 Nov; 97(11):2217-2224. PubMed ID: 30019128
[TBL] [Abstract][Full Text] [Related]
10. Recipient
Nomoto H; Takami A; Espinoza JL; Onizuka M; Kashiwase K; Morishima Y; Fukuda T; Kodera Y; Doki N; Miyamura K; Mori T; Nakao S; Morishita E
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30626079
[TBL] [Abstract][Full Text] [Related]
11. Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants.
Cavet J; Middleton PG; Segall M; Noreen H; Davies SM; Dickinson AM
Blood; 1999 Dec; 94(11):3941-6. PubMed ID: 10572111
[TBL] [Abstract][Full Text] [Related]
12. Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups.
Inamoto Y; Kimura F; Kanda J; Sugita J; Ikegame K; Nakasone H; Nannya Y; Uchida N; Fukuda T; Yoshioka K; Ozawa Y; Kawano I; Atsuta Y; Kato K; Ichinohe T; Inoue M; Teshima T;
Haematologica; 2016 Dec; 101(12):1592-1602. PubMed ID: 27662017
[TBL] [Abstract][Full Text] [Related]
13. Toll-like receptor 1 variation increases the risk of transplant-related mortality in hematologic malignancies.
Uchino K; Mizuno S; Mizutani M; Horio T; Hanamura I; Espinoza JL; Matsuo K; Onizuka M; Kashiwase K; Morishima Y; Fukuda T; Kodera Y; Doki N; Miyamura K; Mori TM; Takami A;
Transpl Immunol; 2016 Sep; 38():60-6. PubMed ID: 27369862
[TBL] [Abstract][Full Text] [Related]
14. A UGT2B17-positive donor is a risk factor for higher transplant-related mortality and lower survival after bone marrow transplantation.
Terakura S; Murata M; Nishida T; Emi N; Akatsuka Y; Riddell SR; Morishima Y; Kodera Y; Naoe T
Br J Haematol; 2005 Apr; 129(2):221-8. PubMed ID: 15813850
[TBL] [Abstract][Full Text] [Related]
15. A single-center analysis of chronic graft-versus-host disease-free, relapse-free survival after alternative donor stem cell transplantation in children with hematological malignancies.
Inagaki J; Fukano R; Noguchi M; Okamura J
Int J Hematol; 2017 May; 105(5):676-685. PubMed ID: 28205066
[TBL] [Abstract][Full Text] [Related]
16. CCR5 deletion mutation and its association with the risk of developing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Bogunia-Kubik K; Duda D; Suchnicki K; Lange A
Haematologica; 2006 Dec; 91(12):1628-34. PubMed ID: 17145599
[TBL] [Abstract][Full Text] [Related]
17. Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Unrelated Allogeneic Bone Marrow Transplantation Facilitated by the Japan Marrow Donor Program.
Miyamoto T; Fukuda T; Nakashima M; Henzan T; Kusakabe S; Kobayashi N; Sugita J; Mori T; Kurokawa M; Mori SI
Biol Blood Marrow Transplant; 2017 Jun; 23(6):938-944. PubMed ID: 28219836
[TBL] [Abstract][Full Text] [Related]
18. Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.
Alousi AM; Brammer JE; Saliba RM; Andersson B; Popat U; Hosing C; Jones R; Shpall EJ; Khouri I; Qazilbash M; Nieto Y; Shah N; Ahmed S; Oran B; Al Atrash G; Ciurea S; Kebriaei P; Chen J; Rondon G; Champlin RE
Biol Blood Marrow Transplant; 2015 May; 21(5):906-12. PubMed ID: 25667989
[TBL] [Abstract][Full Text] [Related]
19. The use of counterflow centrifugal elutriation for the depletion of T cells from unrelated donor bone marrow.
Neudorf SM; Rybka W; Ball E; Blatt J; Bloom E; Corey S; deMagalhaes-Silverman M; Koehler M; Lister J; Mierski J; Mirro J; Pincus S; Wilson J; Wollman M; Donnenberg AD
J Hematother; 1997 Aug; 6(4):351-9. PubMed ID: 9377073
[TBL] [Abstract][Full Text] [Related]
20. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
Russell CA
Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
